Skip to main content
Acta Crystallographica Section F: Structural Biology and Crystallization Communications logoLink to Acta Crystallographica Section F: Structural Biology and Crystallization Communications
. 2006 Jul 25;62(Pt 8):805–807. doi: 10.1107/S1744309106027539

Purification, crystallization and preliminary X-ray diffraction analysis of the glyoxalase II from Leishmania infantum

José Trincão a,, Marta Sousa Silva b,, Lídia Barata a,b, Cecília Bonifácio a, Sandra Carvalho c,d, Ana Maria Tomás c,d, António E N Ferreira b, Carlos Cordeiro b, Ana Ponces Freire b, Maria João Romão a,*
PMCID: PMC2242913  PMID: 16880563

A glyoxalase II from L. infantum was cloned, purified and crystallized and its structure was solved by X-ray crystallography.

Keywords: Leishmania infantum, glyoxalase II, trypanothione

Abstract

In trypanosomatids, trypanothione replaces glutathione in all glutathione-dependent processes. Of the two enzymes involved in the glyoxalase pathway, glyoxalase I and glyoxalase II, the latter shows absolute specificity towards trypanothione thioester, making this enzyme an excellent model to understand the molecular basis of trypanothione binding. Cloned glyoxalase II from Leishmania infantum was overexpressed in Escherichia coli, purified and crystallized. Crystals belong to space group C2221 (unit-cell parameters a = 65.6, b = 88.3, c = 85.2 Å) and diffract beyond 2.15 Å using synchrotron radiation. The structure was solved by molecular replacement using the human glyoxalase II structure as a search model. These results, together with future detailed kinetic characterization using lactoyltrypanothione, should shed light on the evolutionary selection of trypanothione instead of glutathione by trypano­somatids.

1. Introduction

Trypanosomatids, the causal agents of several human and animal diseases worldwide, present two characteristics that set them apart from all other living organisms. Firstly, glycolysis, the most fundamental biochemical pathway, occurs in these organisms within a specific organelle, the glycosome (Hannaert et al., 2003). Secondly, the unique thiol N 1,N 8-bis(glutathionyl)spermidine (trypanothione) replaces glutathione in similar eukaryotic glutathione-dependent reactions (Muller et al., 2003; Fairlamb & Cerami, 1992). These differences may be exploited in the development of novel therapeutic strategies, considering that diseases caused by trypanosomatids have no effective curative therapies and are often lethal. Synergistic effects of simultaneous inhibition of multiple trypanothione-dependent enzymes might prove to be the best option, given the absolute need for this thiol during the life cycle of the parasite (Oza et al., 2003).

The glyoxalase pathway is one of the important systems that depend on trypanothione. In trypanosomatids, this system is composed of the two enzymes glyoxalase I (lactoylglutathione lyase; EC 4.4.1.5) and glyoxalase II (hydroxyacylglutathione hydrolase; EC 3.1.2.6), which are specific for trypanothione and lactoyltrypanothione, respectively (Sousa Silva et al., 2005; Irsch & Krauth-Siegel, 2004). Glyoxalase II shows absolute specificity towards trypanothione thioester, in contrast to glyoxalase I, which can also react with glutathione-methylglyoxal hemithioacetal (Sousa Silva et al., 2005). Thus, it is an excellent model to understand the molecular basis of trypanothione specificity.

L. infantum glyoxalase II is a monomeric protein with 295 residues (molecular weight 32.5 kDa) and shares 35% homology with the human glutathione-dependent glyoxalase II (Cameron et al., 1999). Here, we report the purification, crystallization and preliminary X-­ray diffraction analysis of L. infantum glyoxalase II. Its structure determination will shed some light onto the structure–function relationships of the trypanothione-dependent glyoxalase II.

2. Materials and methods

2.1. Cloning, expression and purification

The LiGLO2 gene was amplified from L. infantum (clone MHOM/MA67ITMAP263) genomic DNA. The PCR product was cloned into the NdeI/XhoI-digested expression vector pET-28a (Novagen), which was then transformed into Escherichia coli BL21-Codon Plus (Stratagene). For overexpression of His6-glyoxalase II, BL21-Codon Plus transformants were grown in LB medium containing 50 µg ml−1 kanamycin and 100 µg ml−1 chloramphenicol at 310 K. When the culture reached an OD600nm of 0.6, expression was induced with 0.2 mM isopropyl β-d-thiogalactopyranoside (IPTG) for 3 h at 310 K. The fusion protein, with an N-terminal tail of six histidines and a thrombin cleavage site (the total tag sequence including linker and cleavage site is HHHHHHSSGLVPRGSH), was purified at 277 K by chromatography on a His-Bind resin (Novagen) column. His6-LiGLO II was eluted with an imidazole gradient from 5 mM to 1 M at a flow rate of 2.5 ml min−1. Fractions containing glyoxalase II (confirmed by SDS–PAGE) were pooled and the buffer was exchanged to 1× PBS pH 7.4 using PD-10 columns (Amersham Biosciences). The purity of the recombinant glyoxalase II was estimated by SDS–PAGE. The His6-LiGLO II was concentrated to 25 mg ml−1 in 10 mM HEPES pH 7.0 using Amicon Ultra-4 filters (10 000 NMWL; Millipore Corporation).

2.2. Crystallization

Crystallization conditions were obtained with an in-house screen of 80 conditions at 293 K, applying the hanging-drop vapour-diffusion method using the crystallization tools from Nextal Biotechnology. Drops were prepared by mixing 2 µl protein solution with 2 µl of each precipitant solution equilibrated over 700 µl reservoir solution. Several conditions in the crystallization screen produced crystals. Crystals were obtained from various conditions including PEGs of molecular weight ranging from 400 to 8000, MES or MOPS with pH between 5.5 and 7.0 and sodium or ammonium acetate as salt components. The best crystals were obtained by mixing 1 µl protein solution with 2 µl reservoir solution containing 30%(w/v) PEG 8000, 0.2 M magnesium chloride and 0.1 M sodium acetate buffer pH 5.5. This final crystallization condition resulted in thick plates, which grew within 2 d to maximum dimensions of approximately 0.16 × 0.06 × 0.02 mm at 288 K (Fig. 1).

Figure 1.

Figure 1

Crystals of L. infantum glyoxalase II.

2.3. Data collection and processing

Crystals were directly flash-cooled in the cryostream without any additional cryoprotectant. All data were collected at 100 K. A low-resolution data set was collected in-house using a Cu Kα Enraf–Nonius rotating-anode generator operated at 5 kW and a MAR Research image-plate detector (Table 1). A high-resolution native data set was measured at beamline ID14-1 at the European Synchrotron Radiation Facility (ESRF) in Grenoble (France) using an ADSC Quantum 4R CCD detector. The crystal diffracted beyond 2.15 Å.

Table 1. Crystal data and data-collection statistics.

Values in parentheses are for the highest resolution shell.

Data set In-house ESRF
Space group C2221
Unit-cell parameters (Å) a = 66.6, b = 90.1, c = 85.8 a = 65.6, b = 88.3, c = 85.2
Source In-house Cu Kα ID14-1
Wavelength (Å) 1.542 0.934
No. of observed reflections 170772 209900
No. of unique reflections 7294 13574
Resolution limits (Å) 30.0–2.7 (2.85–2.7) 30.0–2.15 (2.27–2.15)
Redundancy 6.0 (5.7) 5.4 (5.2)
Rsym (%) 14.2 (47.7) 10.6 (42.5)
Completeness (%) 99.9 (99.9) 98.4 (98.4)
I/σ(I)〉 5.3 (1.6) 5.7 (1.7)

R sym = Inline graphic Inline graphic, where I l is the lth observation of reflection h and 〈I h〉 is the weighted average intensity for all observations l of reflection h.

The diffraction experiments showed that glyoxalase II crystals belong to space group C2221, with unit-cell parameters a = 65.7, b = 88.3, c = 85.2 Å.

The data were processed using MOSFLM v.6.2.5 (Leslie, 1992) and scaled using SCALA from the CCP4 program package v.6.0 (Collaborative Computational Project, Number 4, 1994). In order to estimate the protein content of the asymmetric unit, the Matthews coefficient V M (Matthews, 1968) and solvent content were calculated based on a subunit molecular weight of 32.5 kDa (predicted from the sequence). The structure was solved by molecular replacement using the full structure of the human homologue (PDB code 1qh3; after removing all non-protein atoms) as a search model and the program Phaser (Read, 2001) from the CCP4 suite.

3. Results and discussion

The L. infantum LiGLO2 gene (GenBank accession No. DQ294972) was cloned and expressed in E. coli BL21 Codon Plus cells. The protein was expressed with an N-terminal His-tag fusion. A nickel-affinity column was used for purification. The purity of the recombinant L. infantum His-glyoxalase II was ≥95% as estimated by SDS–PAGE, which showed a single band corresponding to a molecular weight of about 32 kDa.

After optimization of the crystal-growth process, the purified protein produced thick plate crystals within 2 d (Fig. 1) which diffracted beyond 2.15 Å resolution using synchrotron radiation. The crystals belong to space group C2221, with unit-cell parameters a = 65.7, b = 88.3, c = 85.2 Å. The calculated Matthews coefficient is 1.88 Å3 Da−1, corresponding to a solvent content of ∼35%, assuming the presence of one molecule in the asymmetric unit (Matthews, 1968). Data-collection and processing statistics are shown in Table 1.

Molecular replacement was performed using the human glyoxalase II structure (Cameron et al., 1999; PDB code 1qh3; the full model was used), which shows 35% sequence identity with the L. infantum glyoxalase II, as a search model and the molecular-replacement program Phaser (Read, 2001). One clear solution was obtained and the calculated phases were improved using Pirate (Cowtan, 2000). A preliminary Cα trace was manually built from the search model and is currently being rebuilt using COOT (Emsley & Cowtan, 2004) and refined with REFMAC5 from the CCP4 suite (Collaborative Computational Project, Number 4, 1994).

The structure of L. infantum glyoxalase II, together with complete biochemical studies, will provide important insights into the molecular basis of trypanothione specificity.

Acknowledgments

The authors would like to thank the beamline staff at ID14-1 for assistance during data collection at the ESRF, Grenoble, France. This work was supported by projects POCTI/ESP/48272/2002 and BPD- 9444/2002 (JT) from the Fundação para a Ciência e Tecnologia, Ministério da Ciência e Tecnologia, Portugal.

References

  1. Cameron, A. D., Ridderstrom, M., Olin, B. & Mannervik, B. (1999). Structure, 7, 1067–1078. [DOI] [PubMed] [Google Scholar]
  2. Collaborative Computational Project, Number 4 (1994). Acta Cryst. D50, 760–­763. [Google Scholar]
  3. Cowtan, K. (2000). Acta Cryst. D56, 1612–1621. [DOI] [PubMed] [Google Scholar]
  4. Emsley, P. & Cowtan, K. (2004). Acta Cryst. D60, 2126–2132. [DOI] [PubMed] [Google Scholar]
  5. Fairlamb, A. H. & Cerami, A. (1992). Annu. Rev. Microbiol.46, 695–729. [DOI] [PubMed] [Google Scholar]
  6. Hannaert, V., Saavedra, E., Duffieux, F., Szikora, J. P., Rigden, D. J., Michels, P. A. & Opperdoes, F. R. (2003). Proc. Natl Acad. Sci. USA, 100, 1067–1071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Irsch, T. & Krauth-Siegel, R. L. (2004). J. Biol. Chem.279, 22209–22217. [DOI] [PubMed] [Google Scholar]
  8. Leslie, A. G. W. (1992). Jnt CCP4/ESF–EACBM Newsl. Protein Crystallogr.26
  9. Matthews, B. W. (1968). J. Mol. Biol.33, 491–497. [DOI] [PubMed] [Google Scholar]
  10. Muller, S., Liebau, E., Walter, R. D. & Krauth-Siegel, R. L. (2003). Trends Parasitol.19, 320–328. [DOI] [PubMed] [Google Scholar]
  11. Oza, S. L., Ariyanayagam, M. R., Aitcheson, N. & Fairlamb, A. H. (2003). Mol. Biochem. Parasitol.131, 25–33. [DOI] [PubMed] [Google Scholar]
  12. Read, R. J. (2001). Acta Cryst. D57, 1373–1382. [DOI] [PubMed] [Google Scholar]
  13. Sousa Silva, M., Ferreira, A. E., Tomas, A. M., Cordeiro, C. & Ponces Freire, A. (2005). FEBS J.272, 2388–2398. [DOI] [PubMed] [Google Scholar]

Articles from Acta Crystallographica Section F: Structural Biology and Crystallization Communications are provided here courtesy of International Union of Crystallography

RESOURCES